- Home
- KROS vs ORKA Comparison
KROS vs ORKA Comparison
Compare KROS & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- ORKA
- Stock Information
- Founded
- KROS 2015
- ORKA 2004
- Country
- KROS United States
- ORKA United States
- Employees
- KROS N/A
- ORKA N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- KROS Health Care
- ORKA Health Care
- Exchange
- KROS Nasdaq
- ORKA Nasdaq
- Market Cap
- KROS 565.0M
- ORKA 580.3M
- IPO Year
- KROS 2020
- ORKA N/A
- Fundamental
- Price
- KROS $14.52
- ORKA $15.25
- Analyst Decision
- KROS Buy
- ORKA Strong Buy
- Analyst Count
- KROS 14
- ORKA 9
- Target Price
- KROS $20.56
- ORKA $40.38
- AVG Volume (30 Days)
- KROS 413.8K
- ORKA 129.5K
- Earning Date
- KROS 08-06-2025
- ORKA 08-11-2025
- Dividend Yield
- KROS N/A
- ORKA N/A
- EPS Growth
- KROS N/A
- ORKA N/A
- EPS
- KROS 0.47
- ORKA N/A
- Revenue
- KROS $232,844,000.00
- ORKA N/A
- Revenue This Year
- KROS $5,390.70
- ORKA N/A
- Revenue Next Year
- KROS N/A
- ORKA N/A
- P/E Ratio
- KROS $31.11
- ORKA N/A
- Revenue Growth
- KROS 85820.30
- ORKA N/A
- 52 Week Low
- KROS $9.12
- ORKA $5.49
- 52 Week High
- KROS $72.37
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- KROS 56.39
- ORKA N/A
- Support Level
- KROS $13.78
- ORKA N/A
- Resistance Level
- KROS $14.67
- ORKA N/A
- Average True Range (ATR)
- KROS 0.45
- ORKA 0.00
- MACD
- KROS 0.03
- ORKA 0.00
- Stochastic Oscillator
- KROS 82.76
- ORKA 0.00
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.